NCT02874287View on ClinicalTrials.gov

Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 8, 2017

Primary Completion Date

March 1, 2019

Study Completion Date

June 1, 2019

Conditions
Coronary Artery Disease
Interventions
DRUG

Hydroxychloroquine Sulfate Tablets

Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.

DRUG

Placebo Tablets

Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.

Trial Locations (1)

Unknown

First Affiliated Hospital of Xi'an Jiaotong University, Xi’an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT02874287 - Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease. | Biotech Hunter | Biotech Hunter